Core Viewpoint - A class action lawsuit has been filed against Richtech Robotics Inc. for allegedly making false statements regarding its relationship with Microsoft, leading to significant investor losses during the specified class period [8]. Group 1: Allegation Details - The lawsuit claims that Richtech falsely stated it had a collaborative and commercial relationship with Microsoft, which it did not have [8]. - As a result of these misleading statements, the company's business operations and prospects were misrepresented, causing investor damages when the truth was revealed [8]. - Following a critical report questioning the Microsoft deal, Richtech's stock fell by 20.87% on January 29, 2026 [8]. Group 2: Next Steps - Investors who purchased Richtech shares between January 27, 2026, and January 29, 2026, are encouraged to contact the law firm for more information and to discuss their legal rights [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is April 3, 2026 [8]. Group 3: About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various types of litigation, including securities and commercial litigation [5]. - The firm operates nationwide and handles cases in both federal and state courts [5].

Core Viewpoint - A class action lawsuit has been filed against Richtech Robotics Inc. for allegedly making false statements regarding its relationship with Microsoft, leading to significant investor losses during the specified class period [8]. Group 1: Allegations - The lawsuit claims that Richtech falsely stated it had a collaborative and commercial relationship with Microsoft, which it did not have [8]. - As a result of these misleading statements, the company's business operations and prospects were misrepresented, causing investor damages when the truth was revealed [8]. Group 2: Market Reaction - Following the publication of a critical report questioning Richtech's Microsoft collaboration, the company's stock fell by 20.87% on January 29, 2026 [8]. Group 3: Legal Process - Investors who purchased Richtech securities between January 27, 2026, and January 29, 2026, have until April 3, 2026, to apply to be appointed as lead plaintiff in the lawsuit [8].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Arq, Inc. for possible violations of federal securities laws and unlawful business practices affecting stockholders [1][2]. Investigation Details - The investigation is focused on whether Arq has engaged in unlawful activities that may have led to financial losses for investors [1][2]. Financial Performance - On March 9, 2026, Arq reported a GAAP loss per share of $1.20, which was $1.14 below analyst estimates [6]. - Arq provided 2026 revenue guidance of $120 million to $125 million, significantly lower than the consensus estimate of $136.9 million [6]. - Following these disclosures, Arq's stock price dropped by $1.56 per share, or 48.75%, closing at $1.64 per share on March 10, 2026 [6]. Company Actions - Arq's CEO announced a pause on the granular activated carbon production project to conduct a comprehensive review of engineering and production processes, with no firm timeline for completion [6].

Core Viewpoint - A class action lawsuit has been filed against monday.com Ltd. for allegedly misleading investors regarding its revenue outlook and growth projections during the specified class period from September 17, 2025, to February 6, 2026 [2][3] Allegation Details - The complaint claims that monday.com misrepresented its growth potential by suggesting it had reliable information about its projected revenue and expansion, while in reality, it faced decelerating new customer growth, weaker expansion within existing accounts, and longer sales cycles [3] - The company's target of $1.8 billion in revenue for 2027 is now considered increasingly unlikely to be achieved due to these factors [3] Next Steps - Investors who purchased monday.com shares and experienced losses are encouraged to contact the law firm for more information about their rights and potential claims [4]

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. for alleged misrepresentation of financial data and inadequate insurance coverage, impacting investors who acquired shares during the specified class period [6]. Group 1: Allegations - The lawsuit claims that Ardent Health reported inflated accounts receivable and delayed recognizing losses on uncollectable accounts during the class period from July 18, 2024, to November 12, 2025 [6]. - It is alleged that the company did not maintain sufficient professional malpractice liability insurance to cover potential claims arising from its operations [6]. Group 2: Financial Impact - On November 12, 2025, Ardent Health disclosed a $43 million decrease in third quarter 2025 revenue due to revised assessments of accounts receivable collectability, which followed a transition to a new revenue accounting system [6]. - Following this announcement, Ardent Health's stock price dropped by $4.75 per share, a decline of nearly 34%, from $14.05 per share to $9.30 per share on November 13, 2025 [6]. Group 3: Legal Process - Investors who purchased Ardent Health securities during the class period have until March 9, 2026, to apply to the Court to be appointed as lead plaintiff in the lawsuit [6].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) for allegedly misleading investors regarding its competitive position and sales performance in the EP manufacturing market during the specified class period from July 25, 2024, to October 22, 2025 [7]. Allegation Details - The complaint claims that the defendants failed to disclose that the company materially overstated its competitive position within the growing EP manufacturing market [3]. - It is alleged that despite the company's claims of strong visibility into customer demand, it was experiencing a sustained deterioration in sales related to two of its EP devices [3]. - The company mischaracterized its EP devices as a long-term growth driver for its C&V segment, leading to materially false and misleading statements about its business, operations, and prospects [3]. Next Steps - Investors who purchased or acquired Integer shares and suffered losses are encouraged to contact the law firm for more information and to discuss their legal rights [4]. - There is no cost or obligation for investors to reach out regarding their potential claims [4]. - Investors have until February 9, 2026, to apply to the Court to be appointed as lead plaintiff in the lawsuit [7].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Navan, Inc. for possible violations of federal securities laws and unlawful business practices affecting stockholders [1]. Investigation Details - The investigation is focused on whether Navan has engaged in unlawful activities that may have led to financial losses for investors [2]. Financial Performance - Navan conducted its IPO on October 30, 2025, selling approximately 36.9 million shares at $25.00 per share [6]. - The company reported a GAAP loss from operations of $79 million for Q3 fiscal 2026, compared to a loss of $19 million in the same period the previous year [6]. - The GAAP operating margin was reported at -41%, a significant decline from -13% in the same quarter of the previous year [6]. Management Changes - Following the financial results, Navan's CFO stepped down just six weeks post-IPO, receiving benefits including accelerated vesting of restricted stock units and a cash payment of $3.7 million [6]. Stock Price Reaction - On December 16, 2025, Navan's stock price fell by $1.74, or 11.9%, closing at $12.90 per share, indicating a negative market reaction to the financial disclosures and management changes [6].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Lakeland Industries, Inc. for possible violations of federal securities laws and unlawful business practices affecting stockholders [1][2]. Investigation Details - The investigation is focused on whether Lakeland has engaged in unlawful business practices that may have led to financial losses for investors [1][2]. Financial Performance - Lakeland reported third-quarter earnings on December 9, 2025, with net sales of $47.6 million for Q3 2026, and an adjusted EBITDA of $200,000, reflecting a decrease of $4.5 million or 95% compared to the prior year [6]. - The company experienced a net loss of $16 million, equating to ($1.64) per basic and diluted share, in contrast to a net income of $100,000 or $0.01 per share in the same quarter of the previous year [6]. - Following the earnings report, Lakeland's stock price dropped by $5.85 per share, or 38.97%, closing at $9.16 per share on December 10, 2025 [6]. Management Commentary - CEO James Jenkins attributed the poor financial results partly to "delays in certification," indicating that the company anticipated certification to occur in March 2026 [6].

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Limited for allegedly making false and misleading statements regarding its business operations and prospects during the Class Period from February 21, 2025, to August 28, 2025 [3][7]. Allegation Details - The lawsuit claims that defendants materially overstated the progress of Telix's prostate cancer therapeutic candidates [3]. - It is alleged that the quality of Telix's supply chain and partners was also overstated [3]. - As a result of these misrepresentations, statements about Telix's business and operations were materially false and misleading, leading to investor damages when the true details emerged [3]. Next Steps - Investors who purchased Telix shares and suffered losses are encouraged to contact the law firm for more information or to discuss their rights [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is January 9, 2026 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation [5]. - The firm has offices in New York, California, and South Carolina, and specializes in commercial and securities litigation [5].

Core Viewpoint - A class action lawsuit has been filed against F5, Inc. for allegedly providing misleading information regarding its security capabilities, which led to significant financial losses for investors during the specified class period [2][7]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities that purchased F5 securities between October 28, 2024, and October 27, 2025, inclusive [2]. - Investors have until February 17, 2026, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The complaint alleges that F5 made overwhelmingly positive statements while concealing material adverse facts about its security capabilities, specifically regarding a significant security breach affecting key offerings [7]. - The breach reportedly impacted F5's ability to capitalize on the security market, leading to reduced sales and renewals, elongated sales cycles, and increased expenses for remediation efforts [7]. Group 3: Financial Impact - On October 27, 2025, F5 announced fourth quarter fiscal year 2025 results that fell significantly below market growth expectations for fiscal 2026 due to the security breach [7]. - Following the announcement, F5's stock price dropped from $290.41 per share to $258.76 per share, a decline of 10.9% within two days [7].